| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lymphoma, Large B-Cell, Diffuse | 7 | 2025 | 199 | 2.610 |
Why?
|
| Programmed Cell Death 1 Receptor | 8 | 2023 | 188 | 1.880 |
Why?
|
| Leukemia, Myeloid, Acute | 12 | 2021 | 841 | 1.450 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 17 | 2023 | 944 | 1.360 |
Why?
|
| Immunotherapy | 8 | 2023 | 763 | 1.140 |
Why?
|
| Immunotherapy, Adoptive | 7 | 2025 | 277 | 1.120 |
Why?
|
| Tumor Microenvironment | 5 | 2025 | 568 | 1.040 |
Why?
|
| T-Lymphocytes, Regulatory | 4 | 2016 | 350 | 0.950 |
Why?
|
| Hodgkin Disease | 3 | 2021 | 170 | 0.940 |
Why?
|
| Immune Tolerance | 5 | 2017 | 385 | 0.930 |
Why?
|
| T-Lymphocytes | 11 | 2021 | 1316 | 0.920 |
Why?
|
| Antibodies, Bispecific | 1 | 2025 | 37 | 0.890 |
Why?
|
| Antibodies, Monoclonal | 7 | 2023 | 1431 | 0.850 |
Why?
|
| Transplantation Conditioning | 13 | 2020 | 383 | 0.840 |
Why?
|
| B7-H1 Antigen | 6 | 2020 | 305 | 0.820 |
Why?
|
| Lymphoma | 4 | 2020 | 271 | 0.800 |
Why?
|
| Leukemia | 5 | 2019 | 328 | 0.780 |
Why?
|
| Melanoma, Experimental | 3 | 2014 | 111 | 0.720 |
Why?
|
| Tumor Escape | 2 | 2020 | 53 | 0.700 |
Why?
|
| Antigen-Presenting Cells | 3 | 2017 | 145 | 0.690 |
Why?
|
| Graft vs Host Disease | 9 | 2020 | 368 | 0.690 |
Why?
|
| Antineoplastic Agents | 10 | 2023 | 2422 | 0.630 |
Why?
|
| Cell Proliferation | 5 | 2016 | 1761 | 0.600 |
Why?
|
| Homeostasis | 3 | 2012 | 467 | 0.590 |
Why?
|
| Lymphoma, B-Cell | 1 | 2020 | 111 | 0.590 |
Why?
|
| Arabinonucleosides | 3 | 2011 | 39 | 0.570 |
Why?
|
| Neoplasms | 8 | 2018 | 3250 | 0.570 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 8 | 2023 | 2642 | 0.540 |
Why?
|
| Immune Evasion | 1 | 2017 | 37 | 0.520 |
Why?
|
| CD8-Positive T-Lymphocytes | 7 | 2025 | 668 | 0.490 |
Why?
|
| Lymphocyte Activation | 5 | 2019 | 810 | 0.490 |
Why?
|
| Transplantation, Homologous | 16 | 2020 | 1023 | 0.490 |
Why?
|
| Lymphoma, Non-Hodgkin | 4 | 2013 | 271 | 0.470 |
Why?
|
| Immunity, Innate | 3 | 2016 | 464 | 0.460 |
Why?
|
| Antigens, CD19 | 3 | 2025 | 78 | 0.450 |
Why?
|
| Cell Differentiation | 4 | 2025 | 1666 | 0.440 |
Why?
|
| Hematologic Neoplasms | 5 | 2023 | 372 | 0.430 |
Why?
|
| Lymphocyte Depletion | 4 | 2017 | 101 | 0.420 |
Why?
|
| Humans | 56 | 2025 | 96126 | 0.410 |
Why?
|
| Animals | 23 | 2023 | 28945 | 0.410 |
Why?
|
| Thymus Gland | 1 | 2014 | 206 | 0.400 |
Why?
|
| CD40 Antigens | 1 | 2013 | 44 | 0.400 |
Why?
|
| Geriatric Assessment | 4 | 2020 | 192 | 0.380 |
Why?
|
| Signal Transduction | 5 | 2017 | 3586 | 0.380 |
Why?
|
| Mice | 16 | 2023 | 12562 | 0.380 |
Why?
|
| Cross-Priming | 1 | 2012 | 54 | 0.360 |
Why?
|
| Graft vs Tumor Effect | 2 | 2010 | 26 | 0.360 |
Why?
|
| B7-1 Antigen | 3 | 2016 | 75 | 0.350 |
Why?
|
| Antigen Presentation | 3 | 2020 | 229 | 0.340 |
Why?
|
| Mice, Inbred C57BL | 9 | 2016 | 3490 | 0.340 |
Why?
|
| Hepatitis A Virus Cellular Receptor 2 | 2 | 2021 | 8 | 0.330 |
Why?
|
| Cytotoxicity, Immunologic | 2 | 2019 | 218 | 0.330 |
Why?
|
| Adenine Nucleotides | 2 | 2011 | 63 | 0.320 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2010 | 114 | 0.320 |
Why?
|
| Cord Blood Stem Cell Transplantation | 4 | 2017 | 91 | 0.320 |
Why?
|
| Antibodies, Neoplasm | 2 | 2009 | 86 | 0.310 |
Why?
|
| Membrane Proteins | 1 | 2016 | 1276 | 0.310 |
Why?
|
| WT1 Proteins | 1 | 2009 | 21 | 0.300 |
Why?
|
| Salvage Therapy | 1 | 2010 | 238 | 0.300 |
Why?
|
| Rituximab | 4 | 2023 | 133 | 0.290 |
Why?
|
| Antigens, Differentiation | 1 | 2009 | 141 | 0.290 |
Why?
|
| Mice, Knockout | 7 | 2016 | 2163 | 0.270 |
Why?
|
| Membrane Glycoproteins | 1 | 2009 | 453 | 0.250 |
Why?
|
| Leukemia, T-Cell | 1 | 2006 | 17 | 0.250 |
Why?
|
| Transplantation, Autologous | 5 | 2021 | 362 | 0.250 |
Why?
|
| Flow Cytometry | 4 | 2013 | 727 | 0.240 |
Why?
|
| Killer Cells, Natural | 4 | 2021 | 294 | 0.240 |
Why?
|
| Ganciclovir | 1 | 2006 | 52 | 0.240 |
Why?
|
| CD47 Antigen | 2 | 2016 | 24 | 0.240 |
Why?
|
| Valine | 1 | 2006 | 62 | 0.240 |
Why?
|
| Antiviral Agents | 2 | 2007 | 504 | 0.240 |
Why?
|
| Peptides | 1 | 2009 | 672 | 0.230 |
Why?
|
| Acyclovir | 1 | 2006 | 110 | 0.230 |
Why?
|
| Bone Marrow Transplantation | 1 | 2006 | 294 | 0.220 |
Why?
|
| Cytomegalovirus Infections | 1 | 2006 | 155 | 0.220 |
Why?
|
| Cell- and Tissue-Based Therapy | 2 | 2021 | 59 | 0.210 |
Why?
|
| Middle Aged | 23 | 2019 | 28362 | 0.210 |
Why?
|
| Aged | 22 | 2020 | 20963 | 0.210 |
Why?
|
| Survival Analysis | 6 | 2017 | 1546 | 0.210 |
Why?
|
| Male | 26 | 2025 | 45869 | 0.200 |
Why?
|
| Neoplasm Recurrence, Local | 6 | 2023 | 1469 | 0.200 |
Why?
|
| Calreticulin | 2 | 2019 | 16 | 0.200 |
Why?
|
| Lymphoma, Follicular | 1 | 2023 | 74 | 0.200 |
Why?
|
| Interferon Type I | 2 | 2016 | 206 | 0.190 |
Why?
|
| Receptors, Immunologic | 1 | 2023 | 145 | 0.190 |
Why?
|
| Self Tolerance | 2 | 2016 | 27 | 0.190 |
Why?
|
| Cell Separation | 2 | 2013 | 205 | 0.180 |
Why?
|
| Antigens, Neoplasm | 2 | 2016 | 359 | 0.180 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 2 | 2013 | 81 | 0.180 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 2 | 2012 | 67 | 0.180 |
Why?
|
| Histiocytes | 1 | 2021 | 25 | 0.180 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2005 | 423 | 0.180 |
Why?
|
| Cell Line, Tumor | 5 | 2016 | 2794 | 0.170 |
Why?
|
| Disease Models, Animal | 3 | 2016 | 2551 | 0.170 |
Why?
|
| Blood Component Removal | 1 | 2020 | 28 | 0.170 |
Why?
|
| Jehovah's Witnesses | 1 | 2021 | 21 | 0.170 |
Why?
|
| Adult | 18 | 2019 | 28717 | 0.170 |
Why?
|
| Interferon-gamma | 3 | 2013 | 467 | 0.170 |
Why?
|
| Recurrence | 4 | 2017 | 1218 | 0.160 |
Why?
|
| Female | 24 | 2025 | 50062 | 0.160 |
Why?
|
| Rhabdomyosarcoma, Alveolar | 1 | 2019 | 5 | 0.160 |
Why?
|
| Guidelines as Topic | 1 | 2020 | 169 | 0.150 |
Why?
|
| Dendritic Cells | 2 | 2016 | 541 | 0.150 |
Why?
|
| Galectins | 1 | 2019 | 11 | 0.150 |
Why?
|
| Hydrazines | 1 | 2019 | 33 | 0.150 |
Why?
|
| Mitoxantrone | 1 | 2019 | 68 | 0.150 |
Why?
|
| Myelodysplastic Syndromes | 2 | 2017 | 379 | 0.150 |
Why?
|
| Fetal Blood | 2 | 2017 | 96 | 0.150 |
Why?
|
| Genomics | 1 | 2025 | 855 | 0.150 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2020 | 1351 | 0.150 |
Why?
|
| Clinical Trials as Topic | 3 | 2010 | 1178 | 0.150 |
Why?
|
| Interdisciplinary Communication | 1 | 2019 | 135 | 0.150 |
Why?
|
| Cytarabine | 1 | 2019 | 225 | 0.150 |
Why?
|
| Triazoles | 1 | 2019 | 110 | 0.140 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2019 | 152 | 0.140 |
Why?
|
| Melphalan | 2 | 2023 | 100 | 0.140 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2019 | 209 | 0.130 |
Why?
|
| Clonal Anergy | 2 | 2008 | 32 | 0.130 |
Why?
|
| Receptors, Pattern Recognition | 1 | 2017 | 19 | 0.130 |
Why?
|
| Remission Induction | 2 | 2017 | 769 | 0.130 |
Why?
|
| Preoperative Care | 1 | 2019 | 418 | 0.130 |
Why?
|
| Disease Management | 1 | 2019 | 360 | 0.130 |
Why?
|
| Treatment Outcome | 8 | 2019 | 9173 | 0.130 |
Why?
|
| Patient Care Team | 1 | 2019 | 307 | 0.130 |
Why?
|
| Gene Expression Regulation, Leukemic | 2 | 2015 | 99 | 0.130 |
Why?
|
| Drug Therapy, Combination | 2 | 2010 | 813 | 0.130 |
Why?
|
| Health Services Misuse | 1 | 2016 | 21 | 0.130 |
Why?
|
| Xanthones | 1 | 2016 | 11 | 0.120 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2017 | 151 | 0.120 |
Why?
|
| Multiple Myeloma | 1 | 2020 | 354 | 0.120 |
Why?
|
| Haploidy | 1 | 2016 | 32 | 0.120 |
Why?
|
| Paramyxoviridae | 1 | 2015 | 9 | 0.120 |
Why?
|
| Receptors, Antigen, T-Cell | 4 | 2016 | 432 | 0.120 |
Why?
|
| Basic-Leucine Zipper Transcription Factors | 1 | 2016 | 48 | 0.120 |
Why?
|
| Genetic Engineering | 1 | 2016 | 120 | 0.120 |
Why?
|
| Community-Acquired Infections | 1 | 2015 | 65 | 0.120 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2015 | 98 | 0.110 |
Why?
|
| Lymphocyte Subsets | 2 | 2013 | 69 | 0.110 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 1 | 2015 | 132 | 0.110 |
Why?
|
| Immunologic Memory | 1 | 2016 | 188 | 0.110 |
Why?
|
| Immunity | 1 | 2016 | 157 | 0.110 |
Why?
|
| Adaptive Immunity | 1 | 2016 | 180 | 0.110 |
Why?
|
| Respiratory Tract Infections | 1 | 2015 | 117 | 0.110 |
Why?
|
| Receptor, Interferon alpha-beta | 1 | 2014 | 22 | 0.110 |
Why?
|
| Antibodies, Monoclonal, Humanized | 3 | 2011 | 1020 | 0.110 |
Why?
|
| Survival Rate | 4 | 2014 | 1986 | 0.110 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2013 | 380 | 0.110 |
Why?
|
| Mice, Transgenic | 3 | 2013 | 1645 | 0.110 |
Why?
|
| Antigens, CD34 | 4 | 2017 | 163 | 0.110 |
Why?
|
| Gene Expression Regulation | 2 | 2017 | 2059 | 0.100 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 2 | 2012 | 52 | 0.100 |
Why?
|
| Interferon-beta | 1 | 2014 | 126 | 0.100 |
Why?
|
| Toll-Like Receptor 9 | 1 | 2013 | 24 | 0.100 |
Why?
|
| Inflammation | 1 | 2020 | 1068 | 0.100 |
Why?
|
| Haplotypes | 2 | 2013 | 650 | 0.100 |
Why?
|
| Interleukin-18 | 1 | 2013 | 29 | 0.100 |
Why?
|
| Glucocorticoids | 1 | 2015 | 369 | 0.100 |
Why?
|
| STAT3 Transcription Factor | 1 | 2013 | 89 | 0.100 |
Why?
|
| Alemtuzumab | 3 | 2011 | 90 | 0.100 |
Why?
|
| Lymphoma, T-Cell, Peripheral | 1 | 2013 | 33 | 0.100 |
Why?
|
| Transplantation, Haploidentical | 3 | 2017 | 28 | 0.100 |
Why?
|
| Molecular Targeted Therapy | 1 | 2015 | 305 | 0.100 |
Why?
|
| Young Adult | 7 | 2017 | 7025 | 0.100 |
Why?
|
| Epothilones | 1 | 2013 | 13 | 0.100 |
Why?
|
| Repressor Proteins | 1 | 2016 | 447 | 0.100 |
Why?
|
| Intensive Care Units | 1 | 2016 | 460 | 0.100 |
Why?
|
| Prostate | 1 | 2016 | 423 | 0.090 |
Why?
|
| Neovascularization, Pathologic | 1 | 2014 | 355 | 0.090 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2014 | 299 | 0.090 |
Why?
|
| Tumor Cells, Cultured | 2 | 2015 | 1054 | 0.090 |
Why?
|
| Combined Modality Therapy | 3 | 2010 | 1773 | 0.090 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2019 | 647 | 0.090 |
Why?
|
| Translocation, Genetic | 2 | 2019 | 263 | 0.090 |
Why?
|
| Hematopoiesis | 1 | 2013 | 183 | 0.090 |
Why?
|
| Tissue Donors | 2 | 2012 | 542 | 0.090 |
Why?
|
| Cell Movement | 2 | 2016 | 820 | 0.090 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2015 | 611 | 0.090 |
Why?
|
| Graft Survival | 2 | 2013 | 942 | 0.090 |
Why?
|
| Aged, 80 and over | 6 | 2019 | 7232 | 0.090 |
Why?
|
| Leukocyte Transfusion | 1 | 2010 | 15 | 0.090 |
Why?
|
| Cell Survival | 1 | 2013 | 1032 | 0.080 |
Why?
|
| Hospitalization | 1 | 2016 | 943 | 0.080 |
Why?
|
| Prognosis | 5 | 2023 | 4033 | 0.080 |
Why?
|
| Incidence | 3 | 2015 | 1715 | 0.080 |
Why?
|
| Immunomodulation | 1 | 2010 | 64 | 0.080 |
Why?
|
| Graft Rejection | 1 | 2016 | 1126 | 0.080 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2010 | 204 | 0.080 |
Why?
|
| Interleukin-2 | 1 | 2010 | 248 | 0.080 |
Why?
|
| Stem Cell Transplantation | 2 | 2020 | 192 | 0.070 |
Why?
|
| Antigens, CD | 1 | 2010 | 482 | 0.070 |
Why?
|
| Neoplasm Transplantation | 1 | 2009 | 413 | 0.070 |
Why?
|
| Chimerism | 2 | 2020 | 38 | 0.070 |
Why?
|
| Cells, Cultured | 1 | 2013 | 2943 | 0.070 |
Why?
|
| Immunosuppressive Agents | 2 | 2015 | 995 | 0.070 |
Why?
|
| Neoplasm Staging | 2 | 2010 | 2081 | 0.070 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2009 | 176 | 0.070 |
Why?
|
| Down-Regulation | 1 | 2009 | 527 | 0.070 |
Why?
|
| Acute Kidney Injury | 1 | 2011 | 342 | 0.070 |
Why?
|
| Melanoma | 1 | 2011 | 497 | 0.060 |
Why?
|
| Immunity, Cellular | 1 | 2007 | 191 | 0.060 |
Why?
|
| Cyclosporine | 1 | 2007 | 242 | 0.060 |
Why?
|
| Lymphopenia | 1 | 2006 | 32 | 0.060 |
Why?
|
| Models, Animal | 1 | 2007 | 288 | 0.060 |
Why?
|
| Time Factors | 2 | 2013 | 5585 | 0.060 |
Why?
|
| Autoimmune Diseases | 1 | 2007 | 257 | 0.060 |
Why?
|
| Protein Binding | 1 | 2009 | 1561 | 0.060 |
Why?
|
| Neoplasms, Experimental | 1 | 2006 | 271 | 0.060 |
Why?
|
| Disease Progression | 1 | 2009 | 1568 | 0.050 |
Why?
|
| Age Factors | 3 | 2015 | 1963 | 0.050 |
Why?
|
| Mutation | 1 | 2015 | 4374 | 0.050 |
Why?
|
| Pilot Projects | 2 | 2020 | 938 | 0.050 |
Why?
|
| RNA, Small Interfering | 2 | 2015 | 567 | 0.050 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2023 | 147 | 0.050 |
Why?
|
| Histocompatibility Testing | 2 | 2017 | 141 | 0.050 |
Why?
|
| Biological Products | 1 | 2025 | 179 | 0.050 |
Why?
|
| Tumor Burden | 1 | 2023 | 323 | 0.050 |
Why?
|
| Adolescent | 3 | 2016 | 9896 | 0.050 |
Why?
|
| Risk Factors | 3 | 2018 | 5960 | 0.040 |
Why?
|
| Illinois | 2 | 2012 | 531 | 0.040 |
Why?
|
| Health Planning Guidelines | 1 | 2019 | 22 | 0.040 |
Why?
|
| Gene Expression Profiling | 1 | 2006 | 1534 | 0.040 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2021 | 320 | 0.040 |
Why?
|
| Health Plan Implementation | 1 | 2019 | 65 | 0.040 |
Why?
|
| Standard of Care | 1 | 2019 | 70 | 0.040 |
Why?
|
| Interleukin-15 | 1 | 2019 | 76 | 0.040 |
Why?
|
| Vincristine | 1 | 2019 | 113 | 0.040 |
Why?
|
| Disease-Free Survival | 2 | 2012 | 1195 | 0.040 |
Why?
|
| Treatment Failure | 1 | 2019 | 297 | 0.040 |
Why?
|
| Prospective Studies | 2 | 2020 | 4671 | 0.040 |
Why?
|
| Maintenance Chemotherapy | 1 | 2019 | 91 | 0.040 |
Why?
|
| Etoposide | 1 | 2019 | 212 | 0.040 |
Why?
|
| Prednisone | 1 | 2019 | 258 | 0.040 |
Why?
|
| Preoperative Period | 1 | 2018 | 98 | 0.040 |
Why?
|
| Cyclophosphamide | 1 | 2019 | 313 | 0.030 |
Why?
|
| Bone Marrow Cells | 1 | 2019 | 279 | 0.030 |
Why?
|
| Maximum Tolerated Dose | 1 | 2019 | 270 | 0.030 |
Why?
|
| Doxorubicin | 1 | 2019 | 304 | 0.030 |
Why?
|
| Retrospective Studies | 2 | 2023 | 10285 | 0.030 |
Why?
|
| Premedication | 1 | 2017 | 58 | 0.030 |
Why?
|
| Unrelated Donors | 1 | 2017 | 47 | 0.030 |
Why?
|
| Palliative Care | 1 | 2019 | 273 | 0.030 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2019 | 290 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2019 | 873 | 0.030 |
Why?
|
| Cause of Death | 1 | 2018 | 278 | 0.030 |
Why?
|
| Clinical Decision-Making | 1 | 2019 | 296 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2019 | 819 | 0.030 |
Why?
|
| Receptors, CCR7 | 1 | 2016 | 20 | 0.030 |
Why?
|
| B7-2 Antigen | 1 | 2016 | 42 | 0.030 |
Why?
|
| CD8 Antigens | 1 | 2016 | 84 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2018 | 886 | 0.030 |
Why?
|
| Histocompatibility | 1 | 2016 | 66 | 0.030 |
Why?
|
| U937 Cells | 1 | 2015 | 32 | 0.030 |
Why?
|
| Multiplex Polymerase Chain Reaction | 1 | 2015 | 38 | 0.030 |
Why?
|
| Patient Selection | 1 | 2019 | 709 | 0.030 |
Why?
|
| Terminal Care | 1 | 2016 | 146 | 0.030 |
Why?
|
| Comorbidity | 1 | 2018 | 1011 | 0.030 |
Why?
|
| Transplant Recipients | 1 | 2015 | 157 | 0.030 |
Why?
|
| Prevalence | 1 | 2018 | 1349 | 0.030 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2015 | 535 | 0.030 |
Why?
|
| Boronic Acids | 1 | 2013 | 55 | 0.030 |
Why?
|
| Bortezomib | 1 | 2013 | 82 | 0.030 |
Why?
|
| Mice, Inbred NOD | 1 | 2013 | 215 | 0.020 |
Why?
|
| Immunoglobulin Isotypes | 1 | 2013 | 33 | 0.020 |
Why?
|
| Pneumococcal Vaccines | 1 | 2013 | 33 | 0.020 |
Why?
|
| CpG Islands | 1 | 2013 | 169 | 0.020 |
Why?
|
| Mice, SCID | 1 | 2013 | 279 | 0.020 |
Why?
|
| Gene Silencing | 1 | 2013 | 181 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 1 | 2015 | 1125 | 0.020 |
Why?
|
| Lymphocyte Count | 1 | 2013 | 102 | 0.020 |
Why?
|
| Pyrazines | 1 | 2013 | 94 | 0.020 |
Why?
|
| Deoxycytidine | 1 | 2013 | 215 | 0.020 |
Why?
|
| Virus Diseases | 1 | 2013 | 102 | 0.020 |
Why?
|
| Adult Stem Cells | 1 | 2011 | 32 | 0.020 |
Why?
|
| STAT1 Transcription Factor | 1 | 2011 | 58 | 0.020 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 2010 | 72 | 0.020 |
Why?
|
| Glomerular Filtration Rate | 1 | 2011 | 289 | 0.020 |
Why?
|
| Family | 1 | 2012 | 332 | 0.020 |
Why?
|
| Risk | 1 | 2011 | 668 | 0.020 |
Why?
|
| B-Lymphocytes | 1 | 2014 | 771 | 0.020 |
Why?
|
| Lymphatic Metastasis | 1 | 2011 | 514 | 0.020 |
Why?
|
| DNA | 1 | 2015 | 1332 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2014 | 1807 | 0.020 |
Why?
|
| Transcription Factors | 1 | 2016 | 1730 | 0.020 |
Why?
|
| Lymph Nodes | 1 | 2011 | 565 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2014 | 3107 | 0.020 |
Why?
|
| Genes, RAG-1 | 1 | 2006 | 13 | 0.020 |
Why?
|
| Lewis X Antigen | 1 | 2006 | 9 | 0.020 |
Why?
|
| Adoptive Transfer | 1 | 2006 | 175 | 0.020 |
Why?
|
| Myeloid Progenitor Cells | 1 | 2006 | 16 | 0.020 |
Why?
|
| Expressed Sequence Tags | 1 | 2006 | 35 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 11 | 1 | 2006 | 107 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 9 | 1 | 2006 | 80 | 0.010 |
Why?
|
| Gene Library | 1 | 2006 | 134 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 2006 | 395 | 0.010 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2006 | 212 | 0.010 |
Why?
|
| Cost of Illness | 1 | 2005 | 161 | 0.010 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2006 | 701 | 0.010 |
Why?
|
| Cytokines | 1 | 2006 | 872 | 0.010 |
Why?
|
| Neoplasm Metastasis | 1 | 2006 | 1103 | 0.010 |
Why?
|
| Computational Biology | 1 | 2006 | 584 | 0.010 |
Why?
|
| RNA | 1 | 2006 | 606 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2006 | 2092 | 0.010 |
Why?
|
| Apoptosis | 1 | 2006 | 1763 | 0.010 |
Why?
|